SOAT1 and Opportunistic infection: In a phase I double-blind randomized safety clinical study, short-term use of the JAK/STAT signaling pathway inhibitor tofacitinib in subjects with mild-to-moderate SLE was found to be generally safe and well tolerated with no surprises adverse events, thromboembolic events, or opportunistic infections [37].